Abstract
Dysregulation of glutamate neurotransmission has been implicated in schizophrenia primarily because antagonists of the nmethyl- d-aspartate (NMDA) subtype of glutamate receptors exacerbate preexisting symptoms of schizophrenia in patients and produce behavioral disruptions that resemble some symptoms of schizophrenia in healthy individuals. Given this, NMDA receptor antagonists have been used extensively to model aspects of the disease in laboratory animals and have provided a useful preclinical tool for testing novel treatment strategies. More recent genetic and postmortem findings have implicated proteins other than the NMDA receptor in the pathophysiology of schizophrenia which play a role in regulation of the glutamate synapse. Animal models developed based on these findings have the potential of increasing our mechanistic understanding of the disease. Here we review some of the pertinent literature related to pharmacological and genetic animal models of glutamate dysfunction in schizophrenia.
Keywords: NMDA, DISC1, phencyclidine, antipsychotic drugs, metabotropic glutamate receptors, glutamate neurotransmission, glutamate synapse, genetic animal models, schizophrenia, auditory hallucinations
Current Pharmaceutical Design
Title:Glutamatergic Animal Models of Schizophrenia
Volume: 18 Issue: 12
Author(s): Corina Bondi, Marguerite Matthews, Bita Moghaddam
Affiliation:
Keywords: NMDA, DISC1, phencyclidine, antipsychotic drugs, metabotropic glutamate receptors, glutamate neurotransmission, glutamate synapse, genetic animal models, schizophrenia, auditory hallucinations
Abstract: Dysregulation of glutamate neurotransmission has been implicated in schizophrenia primarily because antagonists of the nmethyl- d-aspartate (NMDA) subtype of glutamate receptors exacerbate preexisting symptoms of schizophrenia in patients and produce behavioral disruptions that resemble some symptoms of schizophrenia in healthy individuals. Given this, NMDA receptor antagonists have been used extensively to model aspects of the disease in laboratory animals and have provided a useful preclinical tool for testing novel treatment strategies. More recent genetic and postmortem findings have implicated proteins other than the NMDA receptor in the pathophysiology of schizophrenia which play a role in regulation of the glutamate synapse. Animal models developed based on these findings have the potential of increasing our mechanistic understanding of the disease. Here we review some of the pertinent literature related to pharmacological and genetic animal models of glutamate dysfunction in schizophrenia.
Export Options
About this article
Cite this article as:
Corina Bondi, Marguerite Matthews, Bita Moghaddam , Glutamatergic Animal Models of Schizophrenia , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958576
DOI https://dx.doi.org/10.2174/138161212799958576 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science <i>Qiliqiangxin</i> Prescription Promotes Angiogenesis of Hypoxic Primary Rat Cardiac Microvascular Endothelial Cells via Regulating miR-21 Signaling
Current Pharmaceutical Design Targeting Mitochondria for Cardiac Protection
Current Drug Targets Metabolic Action of Thyroid Hormones: Insights from Functional and Proteomic Studies
Current Proteomics Beneficial Effects of Selective Vitamin D Receptor Activation by Paricalcitol in Chronic Kidney Disease
Current Drug Targets Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Stent Thrombosis - Mythy and Facts
Cardiovascular & Hematological Disorders-Drug Targets GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Current Hypertension Reviews Uncontrolled Hypertension and Oncology: Clinical Tips
Current Vascular Pharmacology Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention (Discontinued) Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Cardio-Hepatic Metabolic Derangements and Valproic Acid
Current Clinical Pharmacology Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Spatial Correlations between the Vacuolation, Prion Protein (PrPsc) Deposits and the Cerebral Blood Vessels in Sporadic Creutzfeldt-Jakob Disease
Current Neurovascular Research Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents